Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II randomized study of first-line therapy comprising bevacizumab and irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) versus bevacizumab and irinotecan hydrochloride and capecitabine (XELIRI) in patients with unresectable metastatic colorectal cancer [ACCORD].

Next Previous
X
Search
Trial Profile

Phase II randomized study of first-line therapy comprising bevacizumab and irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) versus bevacizumab and irinotecan hydrochloride and capecitabine (XELIRI) in patients with unresectable metastatic colorectal cancer [ACCORD].

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms ACCORD

    • Most Recent Events

    • 27 Sep 2011 Follow-up results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 12 Oct 2009 Preliminary results from the first six months of follow-up were presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
    • 22 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top